EQ Equillium: רווח למניה ב-12 החודשים האחרונים

The historical EPS (TTM) price dynamics of Equillium, Inc. (EQ) currently stand at 71.10. The business relies on the development of unique immunomodulators, which could grant the firm market dominance and pricing power over therapy costs. High brand authority is confirmed by the efficacy of itolizumab in combating autoimmune failures. Equillium, Inc. (EQ) is currently actively expanding its drug portfolio, planning to complete key tests by 2026.
פילוחי מדדים פיננסיים ומדדי שוק עבור Equillium, Inc. (EQ)

Equillium, Inc. (EQ) diversification of developments in immunomodulating drugs for the therapy of respiratory and skin pathologies directly impacts profit stability. By analyzing the EPS YoY growth rate (trailing 12 months), an investor assesses the percentage change in net income per share over the past year, which allows for the determination of the business model's real efficiency and the company's resilience to market volatility.